Although repeated analysis of experimental data by the International Stroke and Neurological Disorder Association has identified no evidence for the efficacy of recombinant tissue plasminogen activator (R-TPA) in the first 3 h (8,9), the data also indicated that thrombolytic therapy beyond 3 h is safe (10). The gene discussed is PLAT; the disease is Stroke.